Siemens Healthineers Stages Investor Offensive as Buyback Begins and Guidance Weighs

Siemens Healthineers launches a frantic roadshow and €230M buyback after a 24% YTD slump and downgraded outlook; stock near 52-week low.

Siemens Healthineers is embarking on a frantic two-week roadshow circuit just as a new €230 million share buyback programme gets underway – a dual push to rebuild confidence after a brutal 24% year-to-date slump and a downgraded full-year outlook. The stock, which closed at €33.63, sits barely 1% above its 52-week low of €33.34, leaving management with plenty of explaining to do.

The communication blitz kicked off with yesterday’s BNP Paribas CEO Conference in Paris, followed today by a Berenberg-hosted roadshow in Luxembourg. Next up are the Goldman Sachs Global Healthcare Conference in Miami on June 9, a Bernstein roadshow in Chicago on June 11, and the J.P. Morgan European Healthcare Forum in London on June 18. The timing is no coincidence: the group released second-quarter fiscal 2026 results on May 7 and the market has had little chance to digest them since.

Those numbers paint a mixed picture. The core Imaging division delivered 6.1% comparable growth and an adjusted EBIT margin of 22.4%, while Precision Therapy posted 4.7% growth and a 13.3% margin. Both remain the bedrock of the investment case. But the group-wide comparable revenue growth of just 3.1% tells a different story, dragged down by a 6.5% decline in Diagnostics. The equipment book-to-bill ratio of 1.02 and free cash flow of €389 million were solid, not spectacular – hardly the stuff to re-ignite buying momentum.

Far heavier is the guidance revision. Siemens Healthineers now expects full-year 2026 comparable revenue growth of 4.5-5.0%, down from the previous band of 5-6%. Adjusted diluted earnings per share have been narrowed to €2.20-€2.30, a cut from the earlier ceiling of €2.40. Adjusted EPS for the second quarter came in at €0.53, little changed from a year earlier – no step back, but no step forward either. That stagnation is sure to provoke pointed questions on the roadshow stage.

Meanwhile, the buyback programme that kicked off on June 1 offers a tactical counterweight. The board authorised up to €230 million in share repurchases – a maximum of 14 million shares – to be executed solely on Xetra through to January 29, 2027. The price is capped at plus or minus 10% and 20% of the daily opening price, and daily volume is limited to 25% of the 20-day average turnover. Crucially, the shares are not destined for cancellation; they will be used primarily for employee and executive compensation programmes. That distinguishes this initiative from a traditional capital-reduction buyback and merely offsets dilution from stock-based plans.

At €230 million, the programme is the smallest in a trio of recent repurchase efforts, following a €350 million tranche from March 2025 to January 2026 and a €400 million programme from March 2023 to January 2024. The lower firepower reflects the belt-tightening that the guidance cut implies, even as the stock presents a bargain on paper: its relative strength index sits at 71.4, technically overbought despite a 27% decline over the past twelve months, and the current price is roughly 20% below the 200-day moving average.

No fresh price targets or concrete statements have emerged from the roadshows so far. Whether the management team can deliver enough clarity on growth trajectory and margin prospects to turn the corner – or whether the buyback will be seen as a modest gesture rather than a vote of confidence – will define the next two weeks for investors sitting on painful losses.